Atorvastatin Treatment Prevents Alterations in Coronary Smooth Muscle Nuclear Ca2+ Signaling in Diabetic Dyslipidemia
- 1 June 2002
- journal article
- Published by S. Karger AG in Journal of Vascular Research
- Vol. 39 (3) , 208-220
- https://doi.org/10.1159/000063686
Abstract
Atorvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, alters bulk myoplasmic Ca2+ regulation and inhibits phenotypic modulation and proliferation of vascular smooth muscle in culture. Nuclear Ca2+ (Can) signaling is tightly coupled to transcriptional events and cell growth. Therefore, we hypothesized that in vivo treatment with atorvastatin would attenuate alterations in mitogen-induced Can signaling associated with coronary atherosclerosis. Three groups of male Yucatan pigs were treated for 20 weeks: controls, alloxan-induced diabetics fed an atherogenic diet and diabetics fed an atherogenic diet plus atorvastatin (80 mg/day). Right coronary artery single-cell cytosolic Ca2+ (Cac) and Can responses to the mitogen endothelin-1 (5 × 10–8M) were measured by laser confocal microscopy using the calcium indicator Fluo-4. We observed a 39% increase in Cac and a 52% increase in Can responses to endothelin-1 in cells from diabetic dyslipidemic arteries compared to control. These alterations were prevented in animals treated with atorvastatin. We show that during proliferation, the nucleus of a smooth muscle cell becomes rounded and loses the characteristic multilobular shape, clefts and invaginations. Consistent with this, a redistribution of Ca2+ stores from a transnuclear morphology in controls to a more perinuclear morphology occurred in cells from diabetic dyslipidemic arteries and was prevented by atorvastatin. In addition, the peak Can responses to endothelin-1 were inversely correlated (r = 0.712) with the extent of the transnuclear distribution of Ca2+ stores and directly correlated (r = 0.874) with the extent of atherosclerosis, as assessed in vivo by intravascular ultrasound. These findings indicate that chronic treatment with atorvastatin directly decreases mitogen-induced Can mobilization, which we suggest is related to the spatial localization of Can stores.Keywords
This publication has 12 references indexed in Scilit:
- Functional Nucleotide Receptor Expression and Sarcoplasmic Reticulum Morphology in Dedifferentiated Porcine Coronary Smooth Muscle CellsJournal of Vascular Research, 2001
- Direct visualization of sarcoplasmic reticulum regions discharging Ca2+sparks in vascular myocytesCell Calcium, 2001
- Effect of Statins on Risk of Coronary DiseaseJAMA, 1999
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Bradykinin activates R-, T-, and L-type Ca2+ channels and induces a sustained increase of nuclear Ca2+ in aortic vascular smooth muscle cellsCanadian Journal of Physiology and Pharmacology, 1997
- Simvastatin Releases Ca2+ from a Thapsigargin-Sensitive Pool and Inhibits InsP3-Dependent Ca2+ Mobilization in Vascular Smooth Muscle CellsJournal of Cardiovascular Pharmacology, 1996
- Inositol 1,4,5-Trisphosphate Receptor Is Located to the Inner Nuclear Membrane Vindicating Regulation of Nuclear Calcium Signaling by Inositol 1,4,5-TrisphosphateJournal of Biological Chemistry, 1996
- Diabetes mellitus: A disease of abnormal cellular calcium metabolism?The American Journal of Medicine, 1994
- The pathogenesis of atherosclerosis: a perspective for the 1990sNature, 1993
- Regulation of the mevalonate pathwayNature, 1990